Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01050062
Other study ID # 502.542
Secondary ID
Status Completed
Phase N/A
First received December 24, 2009
Last updated April 4, 2014
Start date January 2010
Est. completion date December 2011

Study information

Verified date April 2014
Source Boehringer Ingelheim
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Observational

Clinical Trial Summary

The survey is conducted to collect safety and effectiveness information in Hypertensive patients treated with Micombi Tablets on the long term use in daily clinical settings in Japan.


Recruitment information / eligibility

Status Completed
Enrollment 1452
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion criteria:

Hypertensive patients who have never taken Micombi Tablets.

Exclusion criteria:

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
Telmisartan 80mg
Combination tablet
Telmisartan 40mg
Combination tablet
Hydrochlorothiazide 12.5mg
Combination tablet

Locations

Country Name City State
Japan Boehringer Ingelheim Investigational Site 111 Ageo
Japan Boehringer Ingelheim Investigational Site 209 Aisho-cho
Japan Boehringer Ingelheim Investigational Site 22 Aizubange-machi
Japan Boehringer Ingelheim Investigational Site 234 Akashi
Japan Boehringer Ingelheim Investigational Site 78 Akiruno
Japan Boehringer Ingelheim Investigational Site 79 Akishima
Japan Boehringer Ingelheim Investigational Site 235 Ako
Japan Boehringer Ingelheim Investigational Site 288 Akune
Japan Boehringer Ingelheim Investigational Site 236 Amagasaki
Japan Boehringer Ingelheim Investigational Site 237 Amagasaki
Japan Boehringer Ingelheim Investigational Site 280 Anan
Japan Boehringer Ingelheim Investigational Site 160 Anjo
Japan Boehringer Ingelheim Investigational Site 1 Asahikawa
Japan Boehringer Ingelheim Investigational Site 51 Ashikaga
Japan Boehringer Ingelheim Investigational Site 140 Atsugi
Japan Boehringer Ingelheim Investigational Site 58 Azumino
Japan Boehringer Ingelheim Investigational Site 128 Chiba
Japan Boehringer Ingelheim Investigational Site 138 Chiba
Japan Boehringer Ingelheim Investigational Site 141 Chigasaki
Japan Boehringer Ingelheim Investigational Site 299 Chikujo-machi
Japan Boehringer Ingelheim Investigational Site 44 Chikusei
Japan Boehringer Ingelheim Investigational Site 80 Chofu
Japan Boehringer Ingelheim Investigational Site 311 Ebino
Japan Boehringer Ingelheim Investigational Site 257 Fuchu
Japan Boehringer Ingelheim Investigational Site 71 Fuefuki
Japan Boehringer Ingelheim Investigational Site 179 Fujieda
Japan Boehringer Ingelheim Investigational Site 211 Fujiidera
Japan Boehringer Ingelheim Investigational Site 112 Fukaya
Japan Boehringer Ingelheim Investigational Site 206 Fukui
Japan Boehringer Ingelheim Investigational Site 300 Fukuoka
Japan Boehringer Ingelheim Investigational Site 301 Fukuoka
Japan Boehringer Ingelheim Investigational Site 302 Fukuoka
Japan Boehringer Ingelheim Investigational Site 303 Fukuoka
Japan Boehringer Ingelheim Investigational Site 180 Fukuroi
Japan Boehringer Ingelheim Investigational Site 23 Fukushima
Japan Boehringer Ingelheim Investigational Site 258 Fukuyama
Japan Boehringer Ingelheim Investigational Site 129 Funabashi
Japan Boehringer Ingelheim Investigational Site 174 Gifu
Japan Boehringer Ingelheim Investigational Site 175 Gifu
Japan Boehringer Ingelheim Investigational Site 42 Gonohe-machi
Japan Boehringer Ingelheim Investigational Site 113 Gyoda
Japan Boehringer Ingelheim Investigational Site 212 Habikino
Japan Boehringer Ingelheim Investigational Site 81 Hachioji
Japan Boehringer Ingelheim Investigational Site 82 Hachioji
Japan Boehringer Ingelheim Investigational Site 193 Hakusan
Japan Boehringer Ingelheim Investigational Site 181 Hamamatsu
Japan Boehringer Ingelheim Investigational Site 247 Hashimoto
Japan Boehringer Ingelheim Investigational Site 142 Hatano
Japan Boehringer Ingelheim Investigational Site 259 Hatsukaichi
Japan Boehringer Ingelheim Investigational Site 276 Higashikagawa
Japan Boehringer Ingelheim Investigational Site 83 Higashikurume
Japan Boehringer Ingelheim Investigational Site 114 Higashimatsuyama
Japan Boehringer Ingelheim Investigational Site 213 Higashiosaka
Japan Boehringer Ingelheim Investigational Site 84 Hino
Japan Boehringer Ingelheim Investigational Site 43 Hirosaki
Japan Boehringer Ingelheim Investigational Site 260 Hiroshima
Japan Boehringer Ingelheim Investigational Site 261 Hiroshima
Japan Boehringer Ingelheim Investigational Site 262 Hiroshima
Japan Boehringer Ingelheim Investigational Site 263 Hiroshima
Japan Boehringer Ingelheim Investigational Site 45 Hitachinaka
Japan Boehringer Ingelheim Investigational Site 266 Hofu
Japan Boehringer Ingelheim Investigational Site 72 Hokuto
Japan Boehringer Ingelheim Investigational Site 249 Ibara
Japan Boehringer Ingelheim Investigational Site 214 Ibaraki
Japan Boehringer Ingelheim Investigational Site 215 Ibaraki
Japan Boehringer Ingelheim Investigational Site 130 Ichikawa
Japan Boehringer Ingelheim Investigational Site 161 Ichinomiya
Japan Boehringer Ingelheim Investigational Site 18 Ichinoseki
Japan Boehringer Ingelheim Investigational Site 19 Ichinoseki
Japan Boehringer Ingelheim Investigational Site 59 Ina
Japan Boehringer Ingelheim Investigational Site 289 Isa
Japan Boehringer Ingelheim Investigational Site 187 Ise
Japan Boehringer Ingelheim Investigational Site 74 Isesaki
Japan Boehringer Ingelheim Investigational Site 182 Ito
Japan Boehringer Ingelheim Investigational Site 52 Iwafune-machi
Japan Boehringer Ingelheim Investigational Site 24 Iwaki
Japan Boehringer Ingelheim Investigational Site 162 Iwakura
Japan Boehringer Ingelheim Investigational Site 216 Izumisano
Japan Boehringer Ingelheim Investigational Site 194 Kaga
Japan Boehringer Ingelheim Investigational Site 290 Kagoshima
Japan Boehringer Ingelheim Investigational Site 73 Kai
Japan Boehringer Ingelheim Investigational Site 195 Kanazawa
Japan Boehringer Ingelheim Investigational Site 53 Kanuma
Japan Boehringer Ingelheim Investigational Site 163 Kariya
Japan Boehringer Ingelheim Investigational Site 238 Kasai
Japan Boehringer Ingelheim Investigational Site 164 Kasugai
Japan Boehringer Ingelheim Investigational Site 115 Kasukabe
Japan Boehringer Ingelheim Investigational Site 217 Kawachinagano
Japan Boehringer Ingelheim Investigational Site 116 Kawaguchi
Japan Boehringer Ingelheim Investigational Site 117 Kawaguchi
Japan Boehringer Ingelheim Investigational Site 231 Kawai-cho
Japan Boehringer Ingelheim Investigational Site 143 Kawasaki
Japan Boehringer Ingelheim Investigational Site 144 Kawasaki
Japan Boehringer Ingelheim Investigational Site 145 Kawasaki
Japan Boehringer Ingelheim Investigational Site 296 Kawatana-cho
Japan Boehringer Ingelheim Investigational Site 40 Kazuno
Japan Boehringer Ingelheim Investigational Site 29 Kesennuma
Japan Boehringer Ingelheim Investigational Site 131 Kisarazu
Japan Boehringer Ingelheim Investigational Site 2 Kitahiroshima
Japan Boehringer Ingelheim Investigational Site 304 Kitakyushu
Japan Boehringer Ingelheim Investigational Site 305 Kitakyushu
Japan Boehringer Ingelheim Investigational Site 306 Kitakyusyu
Japan Boehringer Ingelheim Investigational Site 239 Kobe
Japan Boehringer Ingelheim Investigational Site 240 Kobe
Japan Boehringer Ingelheim Investigational Site 241 Kobe
Japan Boehringer Ingelheim Investigational Site 242 Kobe
Japan Boehringer Ingelheim Investigational Site 25 Koriyama
Japan Boehringer Ingelheim Investigational Site 118 Koshigaya
Japan Boehringer Ingelheim Investigational Site 277 Kotohira
Japan Boehringer Ingelheim Investigational Site 119 Kumagaya
Japan Boehringer Ingelheim Investigational Site 291 Kumamoto
Japan Boehringer Ingelheim Investigational Site 292 Kumamoto
Japan Boehringer Ingelheim Investigational Site 284 Kunisaki
Japan Boehringer Ingelheim Investigational Site 250 Kurashiki
Japan Boehringer Ingelheim Investigational Site 264 Kure
Japan Boehringer Ingelheim Investigational Site 265 Kure
Japan Boehringer Ingelheim Investigational Site 285 Kusu-machi
Japan Boehringer Ingelheim Investigational Site 197 Kyoto
Japan Boehringer Ingelheim Investigational Site 198 Kyoto
Japan Boehringer Ingelheim Investigational Site 199 Kyoto
Japan Boehringer Ingelheim Investigational Site 200 Kyoto
Japan Boehringer Ingelheim Investigational Site 85 Machida
Japan Boehringer Ingelheim Investigational Site 307 Maebaru
Japan Boehringer Ingelheim Investigational Site 146 Matsuda-machi
Japan Boehringer Ingelheim Investigational Site 132 Matsudo
Japan Boehringer Ingelheim Investigational Site 60 Matsumoto
Japan Boehringer Ingelheim Investigational Site 61 Matsumoto
Japan Boehringer Ingelheim Investigational Site 272 Matsuyama
Japan Boehringer Ingelheim Investigational Site 273 Matsuyama
Japan Boehringer Ingelheim Investigational Site 188 Matsuzaka
Japan Boehringer Ingelheim Investigational Site 293 Minamata
Japan Boehringer Ingelheim Investigational Site 30 Minamisanriku-cho
Japan Boehringer Ingelheim Investigational Site 218 Minoo
Japan Boehringer Ingelheim Investigational Site 46 Mito
Japan Boehringer Ingelheim Investigational Site 312 Miyazaki
Japan Boehringer Ingelheim Investigational Site 133 Mobara
Japan Boehringer Ingelheim Investigational Site 20 Morioka
Japan Boehringer Ingelheim Investigational Site 26 Motomiya
Japan Boehringer Ingelheim Investigational Site 3 Mukawa-cho
Japan Boehringer Ingelheim Investigational Site 86 Musashino
Japan Boehringer Ingelheim Investigational Site 62 Nagano
Japan Boehringer Ingelheim Investigational Site 63 Nagano
Japan Boehringer Ingelheim Investigational Site 297 Nagasaki
Japan Boehringer Ingelheim Investigational Site 165 Nagoya
Japan Boehringer Ingelheim Investigational Site 166 Nagoya
Japan Boehringer Ingelheim Investigational Site 167 Nagoya
Japan Boehringer Ingelheim Investigational Site 168 Nagoya
Japan Boehringer Ingelheim Investigational Site 192 Nagoya
Japan Boehringer Ingelheim Investigational Site 314 Naha
Japan Boehringer Ingelheim Investigational Site 41 Nakadori
Japan Boehringer Ingelheim Investigational Site 54 Nakagawa-machi
Japan Boehringer Ingelheim Investigational Site 176 Nakatsugawa
Japan Boehringer Ingelheim Investigational Site 196 Nanao
Japan Boehringer Ingelheim Investigational Site 278 Nankoku
Japan Boehringer Ingelheim Investigational Site 232 Nara
Japan Boehringer Ingelheim Investigational Site 31 Natori
Japan Boehringer Ingelheim Investigational Site 4 Nayoro
Japan Boehringer Ingelheim Investigational Site 313 Nichinan
Japan Boehringer Ingelheim Investigational Site 65 Niigata
Japan Boehringer Ingelheim Investigational Site 66 Niigata
Japan Boehringer Ingelheim Investigational Site 147 Ninomiya-machi
Japan Boehringer Ingelheim Investigational Site 243 Nishinomiya
Japan Boehringer Ingelheim Investigational Site 244 Nishinomiya
Japan Boehringer Ingelheim Investigational Site 169 Nishio
Japan Boehringer Ingelheim Investigational Site 87 Nishitokyo
Japan Boehringer Ingelheim Investigational Site 5 Obihiro
Japan Boehringer Ingelheim Investigational Site 255 Oda
Japan Boehringer Ingelheim Investigational Site 189 Odai-cho
Japan Boehringer Ingelheim Investigational Site 16 Odate
Japan Boehringer Ingelheim Investigational Site 148 Odawara
Japan Boehringer Ingelheim Investigational Site 294 Ogi
Japan Boehringer Ingelheim Investigational Site 286 Oita
Japan Boehringer Ingelheim Investigational Site 287 Oita
Japan Boehringer Ingelheim Investigational Site 251 Okayama
Japan Boehringer Ingelheim Investigational Site 252 Okayama
Japan Boehringer Ingelheim Investigational Site 253 Okayama
Japan Boehringer Ingelheim Investigational Site 308 Omuta
Japan Boehringer Ingelheim Investigational Site 309 Omuta
Japan Boehringer Ingelheim Investigational Site 219 Osaka
Japan Boehringer Ingelheim Investigational Site 220 Osaka
Japan Boehringer Ingelheim Investigational Site 221 Osaka
Japan Boehringer Ingelheim Investigational Site 222 Osaka
Japan Boehringer Ingelheim Investigational Site 223 Osaka
Japan Boehringer Ingelheim Investigational Site 224 Osaka
Japan Boehringer Ingelheim Investigational Site 225 Osaka
Japan Boehringer Ingelheim Investigational Site 226 Osaka
Japan Boehringer Ingelheim Investigational Site 21 Oshu
Japan Boehringer Ingelheim Investigational Site 6 Otaru
Japan Boehringer Ingelheim Investigational Site 210 Otsu
Japan Boehringer Ingelheim Investigational Site 75 Oura-machi
Japan Boehringer Ingelheim Investigational Site 55 Oyama
Japan Boehringer Ingelheim Investigational Site 67 Sado
Japan Boehringer Ingelheim Investigational Site 149 Sagamihara
Japan Boehringer Ingelheim Investigational Site 150 Sagamihara
Japan Boehringer Ingelheim Investigational Site 274 Saijo
Japan Boehringer Ingelheim Investigational Site 120 Saitama
Japan Boehringer Ingelheim Investigational Site 121 Saitama
Japan Boehringer Ingelheim Investigational Site 122 Saitama
Japan Boehringer Ingelheim Investigational Site 227 Sakai
Japan Boehringer Ingelheim Investigational Site 228 Sakai
Japan Boehringer Ingelheim Investigational Site 229 Sakai
Japan Boehringer Ingelheim Investigational Site 39 Sakata
Japan Boehringer Ingelheim Investigational Site 134 Sakura
Japan Boehringer Ingelheim Investigational Site 68 Sanjo
Japan Boehringer Ingelheim Investigational Site 135 Sanmu
Japan Boehringer Ingelheim Investigational Site 267 Sanyoonoda
Japan Boehringer Ingelheim Investigational Site 268 Sanyoonoda
Japan Boehringer Ingelheim Investigational Site 10 Sapporo
Japan Boehringer Ingelheim Investigational Site 11 Sapporo
Japan Boehringer Ingelheim Investigational Site 12 Sapporo
Japan Boehringer Ingelheim Investigational Site 7 Sapporo
Japan Boehringer Ingelheim Investigational Site 8 Sapporo
Japan Boehringer Ingelheim Investigational Site 9 Sapporo
Japan Boehringer Ingelheim Investigational Site 298 Sasebo
Japan Boehringer Ingelheim Investigational Site 123 Satte
Japan Boehringer Ingelheim Investigational Site 124 Sayama
Japan Boehringer Ingelheim Investigational Site 32 Sendai
Japan Boehringer Ingelheim Investigational Site 33 Sendai
Japan Boehringer Ingelheim Investigational Site 34 Sendai
Japan Boehringer Ingelheim Investigational Site 35 Sendai
Japan Boehringer Ingelheim Investigational Site 36 Sendai
Japan Boehringer Ingelheim Investigational Site 37 Sendai
Japan Boehringer Ingelheim Investigational Site 69 Shibata
Japan Boehringer Ingelheim Investigational Site 13 Shibetsu
Japan Boehringer Ingelheim Investigational Site 125 Shiki
Japan Boehringer Ingelheim Investigational Site 279 Shimanto
Japan Boehringer Ingelheim Investigational Site 310 Shime-machi
Japan Boehringer Ingelheim Investigational Site 183 Shimoda
Japan Boehringer Ingelheim Investigational Site 248 Shingu
Japan Boehringer Ingelheim Investigational Site 38 Shiraishi
Japan Boehringer Ingelheim Investigational Site 136 Shiroi
Japan Boehringer Ingelheim Investigational Site 184 Shizuoka
Japan Boehringer Ingelheim Investigational Site 185 Shizuoka
Japan Boehringer Ingelheim Investigational Site 269 Shunan
Japan Boehringer Ingelheim Investigational Site 126 Soka
Japan Boehringer Ingelheim Investigational Site 27 Sukagawa
Japan Boehringer Ingelheim Investigational Site 190 Suzuka
Japan Boehringer Ingelheim Investigational Site 88 Tachikawa
Japan Boehringer Ingelheim Investigational Site 203 Takaoka
Japan Boehringer Ingelheim Investigational Site 204 Takaoka
Japan Boehringer Ingelheim Investigational Site 245 Takarazuka
Japan Boehringer Ingelheim Investigational Site 76 Takasaki
Japan Boehringer Ingelheim Investigational Site 77 Takasaki
Japan Boehringer Ingelheim Investigational Site 177 Takayama
Japan Boehringer Ingelheim Investigational Site 246 Tatsuno
Japan Boehringer Ingelheim Investigational Site 47 Tokai-mura
Japan Boehringer Ingelheim Investigational Site 70 Tokamachi
Japan Boehringer Ingelheim Investigational Site 170 Tokoname
Japan Boehringer Ingelheim Investigational Site 127 Tokorozawa
Japan Boehringer Ingelheim Investigational Site 281 Tokushima
Japan Boehringer Ingelheim Investigational Site 282 Tokushima
Japan Boehringer Ingelheim Investigational Site 89 Tokyo Adachi-ku
Japan Boehringer Ingelheim Investigational Site 90 Tokyo Adachi-ku
Japan Boehringer Ingelheim Investigational Site 102 Tokyo Bunkyo-ku
Japan Boehringer Ingelheim Investigational Site 91 Tokyo Chiyoda-ku
Japan Boehringer Ingelheim Investigational Site 92 Tokyo Chiyoda-ku
Japan Boehringer Ingelheim Investigational Site 93 Tokyo Kita-ku
Japan Boehringer Ingelheim Investigational Site 94 Tokyo Koto-ku
Japan Boehringer Ingelheim Investigational Site 95 Tokyo Meguro-ku
Japan Boehringer Ingelheim Investigational Site 96 Tokyo Meguro-ku
Japan Boehringer Ingelheim Investigational Site 97 Tokyo Nerima-ku
Japan Boehringer Ingelheim Investigational Site 98 Tokyo Ota-ku
Japan Boehringer Ingelheim Investigational Site 99 Tokyo Ota-ku
Japan Boehringer Ingelheim Investigational Site 100 Tokyo Setagaya-ku
Japan Boehringer Ingelheim Investigational Site 101 Tokyo Setagaya-ku
Japan Boehringer Ingelheim Investigational Site 103 Tokyo Shibuya-ku
Japan Boehringer Ingelheim Investigational Site 104 Tokyo Shinagawa-ku
Japan Boehringer Ingelheim Investigational Site 105 Tokyo Shinagawa-ku
Japan Boehringer Ingelheim Investigational Site 106 Tokyo Shinagawa-ku
Japan Boehringer Ingelheim Investigational Site 107 Tokyo Shinjuku-ku
Japan Boehringer Ingelheim Investigational Site 108 Tokyo Suginami-ku
Japan Boehringer Ingelheim Investigational Site 109 Tokyo Sumida-ku
Japan Boehringer Ingelheim Investigational Site 110 Tokyo Toshima-ku
Japan Boehringer Ingelheim Investigational Site 14 Tomakomai
Japan Boehringer Ingelheim Investigational Site 28 Tomioka-machi
Japan Boehringer Ingelheim Investigational Site 295 Tosu
Japan Boehringer Ingelheim Investigational Site 270 Tottori
Japan Boehringer Ingelheim Investigational Site 15 Toyako-machi
Japan Boehringer Ingelheim Investigational Site 205 Toyama
Japan Boehringer Ingelheim Investigational Site 171 Toyohashi
Japan Boehringer Ingelheim Investigational Site 172 Toyokawa
Japan Boehringer Ingelheim Investigational Site 230 Toyonaka
Japan Boehringer Ingelheim Investigational Site 173 Toyota
Japan Boehringer Ingelheim Investigational Site 49 Tsuchiura
Japan Boehringer Ingelheim Investigational Site 207 Tsuruga
Japan Boehringer Ingelheim Investigational Site 208 Tsuruga
Japan Boehringer Ingelheim Investigational Site 283 Tsurugi-cho
Japan Boehringer Ingelheim Investigational Site 254 Tsuyama
Japan Boehringer Ingelheim Investigational Site 64 Ueda
Japan Boehringer Ingelheim Investigational Site 201 Uji
Japan Boehringer Ingelheim Investigational Site 48 Ushiku
Japan Boehringer Ingelheim Investigational Site 56 Utsunomiya
Japan Boehringer Ingelheim Investigational Site 57 Utsunomiya
Japan Boehringer Ingelheim Investigational Site 275 Uwajima
Japan Boehringer Ingelheim Investigational Site 137 Yachimata
Japan Boehringer Ingelheim Investigational Site 186 Yaizu
Japan Boehringer Ingelheim Investigational Site 178 Yamagata
Japan Boehringer Ingelheim Investigational Site 151 Yamato
Japan Boehringer Ingelheim Investigational Site 233 Yamatokooriyama
Japan Boehringer Ingelheim Investigational Site 191 Yokkaichi
Japan Boehringer Ingelheim Investigational Site 152 Yokohama
Japan Boehringer Ingelheim Investigational Site 153 Yokohama
Japan Boehringer Ingelheim Investigational Site 154 Yokohama
Japan Boehringer Ingelheim Investigational Site 155 Yokohama
Japan Boehringer Ingelheim Investigational Site 156 Yokohama
Japan Boehringer Ingelheim Investigational Site 157 Yokohama
Japan Boehringer Ingelheim Investigational Site 158 Yokohama
Japan Boehringer Ingelheim Investigational Site 159 Yokosuka
Japan Boehringer Ingelheim Investigational Site 271 Yonago
Japan Boehringer Ingelheim Investigational Site 202 Yosano-cho
Japan Boehringer Ingelheim Investigational Site 256 Yoshika-cho
Japan Boehringer Ingelheim Investigational Site 139 Yotsukaido
Japan Boehringer Ingelheim Investigational Site 50 Yuki
Japan Boehringer Ingelheim Investigational Site 17 Yurihonjo

Sponsors (2)

Lead Sponsor Collaborator
Boehringer Ingelheim Astellas Pharma Inc

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Adverse Events (AEs) The number of patient with any AEs, patients with drug-related AEs Week 52 No
Secondary Systolic Blood Pressure (SBP) SBP is observed at Week 0 and Week 52. The change of SBP from Week 0 to Week 52 is calculated. Week 0 and Week 52 No
Secondary Diastolic Blood Pressure (DBP) DBP is observed at Week 0 and Week 52. The change of DBP from Week 0 to Week 52 is calculated. Week 0 and Week 52 No
Secondary Target Blood Pressure Achievement Rate The proportion of the patients with target blood pressure in 52 weeks administrative period. Target blood pressure is defined as 'Guidelines for the management of hypertension (JSH2009)': less than 140/90 (SBP/DBP) mmHg for >= 65 years old or cerebrovascular disorder patient; less than 130/80 in diabetes, chronic kidney disease or myocardial infarction patient; less than 130/85 mmHg for others patient. Week 52 No
Secondary Blood Pressure Normalised Rate The proportion of the patients with normalized blood pressure in 52 weeks on administrative period. Normalized blood pressure is defined less than 140/90 (SBP/DBP) mmHg according to JSH2009 Week 52 No
See also
  Status Clinical Trial Phase
Terminated NCT04591808 - Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia Phase 3
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Completed NCT03093532 - A Hypertension Emergency Department Intervention Aimed at Decreasing Disparities N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT05529147 - The Effects of Medication Induced Blood Pressure Reduction on Cerebral Hemodynamics in Hypertensive Frail Elderly
Recruiting NCT05976230 - Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Completed NCT06008015 - A Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1015" and Co-administration of "BR1015-1" and "BR1015-2" Under Fed Conditions in Healthy Volunteers Phase 1
Completed NCT05387174 - Nursing Intervention in Two Risk Factors of the Metabolic Syndrome and Quality of Life in the Climacteric Period N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Recruiting NCT05121337 - Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension N/A
Withdrawn NCT04922424 - Mechanisms and Interventions to Address Cardiovascular Risk of Gender-affirming Hormone Therapy in Trans Men Phase 1
Active, not recruiting NCT05062161 - Sleep Duration and Blood Pressure During Sleep N/A
Not yet recruiting NCT05038774 - Educational Intervention for Hypertension Management N/A
Completed NCT05087290 - LOnger-term Effects of COVID-19 INfection on Blood Vessels And Blood pRessure (LOCHINVAR)
Completed NCT05621694 - Exploring Oxytocin Response to Meditative Movement N/A
Completed NCT05688917 - Green Coffee Effect on Metabolic Syndrome N/A
Recruiting NCT05575453 - OPTIMA-BP: Empowering PaTients in MAnaging Blood Pressure N/A